{"id":3932,"date":"2025-09-22T15:14:22","date_gmt":"2025-09-22T13:14:22","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3932"},"modified":"2025-09-22T15:14:22","modified_gmt":"2025-09-22T13:14:22","slug":"hosio-antti","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/hosio-antti\/","title":{"rendered":"Hosio Antti"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">.shortcode-single-image-wrap.shortcode-single-image-fbb61a68e3493c924e278b8ce4c54a9f.enable-bg-rollover .rollover i,\n.shortcode-single-image-wrap.shortcode-single-image-fbb61a68e3493c924e278b8ce4c54a9f.enable-bg-rollover .rollover-video i {\n  background: -webkit-linear-gradient();\n  background: linear-gradient();\n}\n.shortcode-single-image-wrap.shortcode-single-image-fbb61a68e3493c924e278b8ce4c54a9f .rollover-icon {\n  font-size: 32px;\n  color: #ffffff;\n  min-width: 44px;\n  min-height: 44px;\n  line-height: 44px;\n  border-radius: 100px;\n  border-style: solid;\n  border-width: 0px;\n}\n.dt-icon-bg-on.shortcode-single-image-wrap.shortcode-single-image-fbb61a68e3493c924e278b8ce4c54a9f .rollover-icon {\n  background: rgba(255,255,255,0.3);\n  box-shadow: none;\n}<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-fbb61a68e3493c924e278b8ce4c54a9f alignnone  vc_custom_1758545271324 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hosio_foto-500x500.jpg\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hosio_foto-500x500.jpg 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hosio_foto-1000x1000.jpg 1000w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/hosio_foto\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>Dr Antti Hosio<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-81869f2fafe9e151\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-81869f2fafe9e151 uvc-3029 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-81869f2fafe9e151 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-81869f2fafe9e151 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Dr Antti Hosio, MD, is a\u00a0 Clinical Oncologist at the Comprehensive Cancer Centre of Helsinki University Hospital, where his main interest is in pharmacotherapies of gastrointestinal cancers and palliative medicine. Dr Hosio has participated in several clinical trials aiming to develop treatment options for colorectal cancer patients. Hosio is a\u00a0Doctoral researcher in the Pharmacogenetics research group at the University of Helsinki.<\/div><\/div><div id=\"ultimate-heading-349369f2fafe9e1a8\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-349369f2fafe9e1a8 uvc-1498 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-349369f2fafe9e1a8 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-349369f2fafe9e1a8 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\"><strong>Implementing <em>DPYD <\/em>genotyping in Finland: impact on fluoropyrimidine exposure and safety<\/strong><\/p>\n<p>Fluoropyrimidines 5-fluorouracil, capecitabine, and tegafur are commonly used anti-cancer drugs in the treatment of various solid tumors. Historically, severe toxicities have occurred in up to 30% of patients receiving 5-fluorouracil or capecitabine and have led to fatalities in 0.5-2% of patients. An important cause of toxicity is reduced dihydropyrimidine dehydrogenase (DPD) enzyme activity accounting for up to 50-75% of the severe fluoropyrimidine toxicities and most of the lethal toxicities. Variations in the <em>DPYD <\/em>gene, encoding DPD, determine enzyme activity and might increase the risk for drug accumulation and toxic effects. Pre-emptive testing of <em>DPYD<\/em> variants followed by genotype-guided dose adjustments reduce fluoropyrimidine-related toxicities and subsequent hospitalization while being cost-effective. The Clinical Pharmacogenetics Implementation Consortium has published guidelines for fluoropyrimidine dose modification for genetically intermediate or poor DPD metabolizers. The European Medicines Agency recommends testing for DPD deficiency, and in Finland, pre-emptive<em> DPYD<\/em> genotyping has been part of standard care in the treatment of fluoropyrimidine-receiving patients since 2019. An observational clinical trial investigating the impact of implementing<em> DPYD <\/em>genotype testing into routine practice in Finnish breast and colorectal cancer patients has been carried out in Finnish cancer centres since 2019. Results from this study will be presented.<\/p>\n<p>&nbsp;<\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3932","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3932"}],"version-history":[{"count":3,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3932\/revisions"}],"predecessor-version":[{"id":3935,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3932\/revisions\/3935"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}